⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HURA News
TuHURA Biosciences, Inc. Common Stock
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
prnewswire.com
HURA
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
prnewswire.com
HURA
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
prnewswire.com
HURA
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
prnewswire.com
HURA
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
prnewswire.com
HURA
TuHURA Biosciences Provides Corporate Update Following Recent Financing
prnewswire.com
HURA
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
prnewswire.com
HURA
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
prnewswire.com
HURA
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
prnewswire.com
HURA